文献速递造血干细胞移植与细胞治疗白血病

工程化T细胞抑制异基因造血干细胞移植后急性GVHD与白血病复发

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood · 2023-01-01

急性移植物抗宿主病(aGVHD)限制异基因造血干细胞移植(allo-HSCT)获益。研究显示OX40在aGVHD患者循环T细胞及恒河猴GVHD靶器官浸润T细胞中上调,据此构建OX40特异性细胞毒受体T细胞,可选择性清除OX40+ T细胞、抑制同种反应性T细胞扩增,且不抑制EBV、CMV、腺病毒特异性记忆T细胞抗病毒活性;小鼠模型中全身给药完全保护免于致死性异种GVHD,与白血病特异性CAR联合可在移植后残留病模型中同时抗白血病和aGVHD。

要点

  • OX40在aGVHD患者循环T细胞及恒河猴GVHD靶器官浸润T细胞中上调。
  • OX40特异性T细胞对活化CD4+ T细胞有强细胞毒作用并抑制同种反应性T细胞扩增。
  • OX40靶向不抑制EBV、CMV、腺病毒特异性记忆T细胞抗病毒活性。

核心结论

  • OX40+ T细胞在介导aGVHD发病中起核心作用,支持源自干细胞供者的双功能工程化T细胞产品在allo-HSCT后同时抑制疾病复发和aGVHD的可行性。

研究设计与样本

  • 研究包括恒河猴GVHD模型、人T细胞体外实验及小鼠异种GVHD与移植后残留病模型。

主要发现

  • 恒河猴模型中OX40在浸润GVHD靶器官的T细胞上上调。
  • 工程化OX40特异性T细胞在混合淋巴细胞反应模型中介导对活化CD4+ T细胞的强细胞毒作用并抑制同种反应性T细胞扩增。
  • OX40靶向不抑制EBV、CMV和腺病毒抗原特异性记忆T细胞的抗病毒活性。
  • 全身给予OX40靶向T细胞使小鼠完全免于由人外周血单个核细胞介导的致死性异种GVHD。
  • 在小鼠移植后残留病异种移植模型中,将OX40靶向与白血病特异性嵌合抗原受体组合于单一T细胞产品可同时提供抗白血病和抗aGVHD保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) limits the therapeutic benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and requires immunosuppressive prophylaxis that compromises antitumor and antipathogen immunity. OX40 is a costimulatory receptor upregulated on circulating T cells in aGVHD and plays a central role in driving the expansion of alloreactive T cells. Here, we show that OX40 is also upregulated on T cells infiltrating GVHD target organs in a rhesus macaque model, supporting the hypothesis that targeted ablation of OX40+ T cells will mitigate GVHD pathogenesis. We thus created an OX40-specific cytotoxic receptor that, when expressed on human T cells, enables selective elimination of OX40+ T cells. Because OX40 is primarily upregulated on CD4+ T cells upon activation, engineered OX40-specific T cells mediated potent cytotoxicity against activated CD4+ T cells and suppressed alloreactive T-cell expansion in a mixed lymphocyte reaction model. OX40 targeting did not inhibit antiviral activity of memory T cells specific to Epstein-Barr virus, cytomegalovirus, and adenoviral antigens. Systemic administration of OX40-targeting T cells fully protected mice from fatal xenogeneic GVHD mediated by human peripheral blood mononuclear cells. Furthermore, combining OX40 targeting with a leukemia-specific chimeric antigen receptor in a single T cell product provides simultaneous protection against leukemia and aGVHD in a mouse xenograft model of residual disease posttransplant. These results underscore the central role of OX40+ T cells in mediating aGVHD pathogenesis and support the feasibility of a bifunctional engineered T-cell product derived from the stem cell donor to suppress both disease relapse and aGVHD following allo-HSCT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mo F, Watanabe N, Omdahl KI, et al. Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023. PMID: 36044667. doi:10.1182/blood.2022016052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。